Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Brixen

Showing results (111-120 of 137) with videos related to

Pageof 14
Sort By:
Endocrine|January 18, 2013
Genetic association study of WNT10B polymorphisms with BMD and adiposity parameters in Danish and Belgian malesJasmijn K Van Camp, Sigri Beckers, Doreen Zegers, et al.
Calcified Tissue International|January 13, 2015
The risk-stratified osteoporosis strategy evaluation study (ROSE): a randomized prospective population-based study. Design and baseline characteristicsKatrine Hass Rubin, Teresa Holmberg, Mette Juel Rothmann, et al.
European Journal of Endocrinology|December 26, 2001
Increased risk of osteoporotic fractures in patients with Cushing's syndromePeter Vestergaard, Jørgen Lindholm, Jens Otto L Jørgensen, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 20, 2014
Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strengthAngela M Cheung, Sharmila Majumdar, Kim Brixen, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 4, 2006
Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and olderEgo Seeman, Bruno Vellas, Claude Benhamou, et al.
The Journal of Clinical Endocrinology and Metabolism|January 23, 2013
Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trialKim Brixen, Roland Chapurlat, Angela M Cheung, et al.
Thrombosis and Haemostasis|February 1, 2007
Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapyMoniek P M de Maat, Jonna Skov Madsen, Bente Langdahl, et al.
Clinical Endocrinology|March 5, 2002
Fracture risk is increased in patients with GH deficiency or untreated prolactinomas--a case-control studyPeter Vestergaard, Jens Otto L Jørgensen, Claus Hagen, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 4, 2008
Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)Richard Eastell, Thomas Nickelsen, Fernando Marin, et al.
Arthritis and Rheumatism|June 3, 2008
Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trialJean-Yves Reginster, Dieter Felsenberg, Steven Boonen, et al.
Pageof 14

Showing results (111-120 of 137) with videos related to

Sort By:
Pageof 14
Endocrine|January 18, 2013
Genetic association study of WNT10B polymorphisms with BMD and adiposity parameters in Danish and Belgian malesJasmijn K Van Camp, Sigri Beckers, Doreen Zegers, et al.
Calcified Tissue International|January 13, 2015
The risk-stratified osteoporosis strategy evaluation study (ROSE): a randomized prospective population-based study. Design and baseline characteristicsKatrine Hass Rubin, Teresa Holmberg, Mette Juel Rothmann, et al.
European Journal of Endocrinology|December 26, 2001
Increased risk of osteoporotic fractures in patients with Cushing's syndromePeter Vestergaard, Jørgen Lindholm, Jens Otto L Jørgensen, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 20, 2014
Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strengthAngela M Cheung, Sharmila Majumdar, Kim Brixen, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 4, 2006
Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and olderEgo Seeman, Bruno Vellas, Claude Benhamou, et al.
The Journal of Clinical Endocrinology and Metabolism|January 23, 2013
Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trialKim Brixen, Roland Chapurlat, Angela M Cheung, et al.
Thrombosis and Haemostasis|February 1, 2007
Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapyMoniek P M de Maat, Jonna Skov Madsen, Bente Langdahl, et al.
Clinical Endocrinology|March 5, 2002
Fracture risk is increased in patients with GH deficiency or untreated prolactinomas--a case-control studyPeter Vestergaard, Jens Otto L Jørgensen, Claus Hagen, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 4, 2008
Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)Richard Eastell, Thomas Nickelsen, Fernando Marin, et al.
Arthritis and Rheumatism|June 3, 2008
Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trialJean-Yves Reginster, Dieter Felsenberg, Steven Boonen, et al.
Pageof 14